Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05020912 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 28 to confirmed 18
    • Eligibility criteria expanded, about 19 words
    • Site details revised
    v10
  2. 2 versions Re-verified since Nov 13, 2024, no change to tracked fieldsv8-v9
  3. Eligibility criteria revisedv7
  4. Primary completion date: Jun 2023 to Sep 2027
    • Start date: Nov 9, 2021 to Dec 13, 2021
    • Study completion date: Jun 2024 to Dec 2027
    v6
  5. Re-verified, no change to tracked fieldsv5
Show 3 earlier versionsHide 3 earlier versions
  1. Secondary endpoints: 7 to 8v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 2022 to Nov 9, 2021
    • Site details revised
    v3
  3. Start date: Sep 2021 to Jan 2022v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to better understand the immune response to basal cell carcinoma (BCC) treated with Photodynamic Therapy (PDT) in order to develop new methods of treating BCC. Previous research suggests that PDT alters the immune response, possibly in a way that could promote better tumor clearance when combined with other treatments. Overall, participation in this study will help the study team better understand the anti-tumor immune response when BCC is treated with PDT.
Trial Details
NCT Number NCT05020912
Lead Sponsor Case Comprehensive Cancer Center
Conditions
(from sponsor)		 Basal Cell Carcinoma
Related terms Basal Cell Carcinoma
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov